BHVN Latest Press Releases

-- November 5, 2026 --

Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting PRNewswire 7:30 AM

-- October 29, 2026 --

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results PRNewswire 4:03 PM

-- October 26, 2026 --

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy PRNewswire 7:31 AM

-- October 8, 2026 --

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease PRNewswire 4:01 AM

-- September 28, 2026 --

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 PRNewswire 7:31 AM

-- September 11, 2026 --

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) PRNewswire 6:28 PM

-- August 26, 2026 --

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy PRNewswire 2:37 AM

-- August 25, 2026 --

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University PRNewswire 4:43 PM

-- August 10, 2026 --

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results PRNewswire 4:02 PM

-- August 6, 2026 --

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors PRNewswire 7:00 AM

-- July 27, 2026 --

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million PRNewswire 7:00 AM

-- July 20, 2026 --

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload PRNewswire 7:30 AM

-- July 9, 2026 --

Biohaven Announces Scientific Leadership Transitions PRNewswire 5:00 PM

-- June 30, 2026 --

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator PRNewswire 7:30 AM

-- June 29, 2026 --

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease PRNewswire 7:30 AM

Market Data Delayed 15 Minutes